@J FYI I have moved my posts to the KRMD board.

Earnings Tuesday, Novebmer 5ty after close.

insert-text-here

@JLivermore- in retrospect, its easy to see that the Q3 earnings date and announcement were delayed to after the conference. This allowed time for the re branding and the release of the super26 needle set study.

KORU Medical Systems to Present Poster Featuring HIgH-Flo Super26™ Needle Set at IgNS 2019 National Conference

https://www.korumedical.com/investors/news-events/press-releases/detail/47/koru-medical-systems-to-present-poster-featuring-high-flo

decreased SCIg infusion time for 88% of patients as compared to the standard HIgHFlo™26G needle set, with a median improvement time of 33%;

I should have read the headlines for conference abstracts before prior posting. Note highlighted at bottom. The super26 needle set study results will be release at conference. My guess is this is why all hand are on deck there!! Major product lunch is imminent and close?!

https://ignsconference.com/36-study-to-evaluate-patient-centered-outcomes-and-infusion-parameters-using-the-rms-highflo-super-26-needle-set-vs-rms-standard-highflo-26gauge-needle-set-in-patients-with-primary-immunodeficiency/

The Super 26 needle is FDA-cleared but has yet to be released for commercial or clinical use on a larger scale. Patient-completed surveys captured infusion parameters, satisfaction scores, and incidental (minor) adverse events at each of 8 infusions (4 infusions with standard 26g needles vs. 4 infusions with Super 26g needles). Each subject will serve as his/her own control. Paired analysis of variance will be used to assess for differences in continuous variables and chi squared tests will be used to assess dichotomous variables. Results: Study is currently ongoing and results will be available at the time of conference presentation. Discussion: Study is currently ongoing and discussion will be available at the time of conference presentation. Conclusions: Study is currently ongoing and conclusion will be available at the time of conference presentation.[color=red][/color]

RMS MEDICAL IS A SPONSOR AND AN EXHIBITOR


IgNS 2019 National Conference. Ig National Society will hold its 8th Annual National Conference at the Red Rock Casino Resort & Spa on October 24-27, 2019. Nurses, pharmacists, physicians, and industry leaders will convene for the only multidisciplinary, comprehensive Ig therapy conference.
IgNS 2019 National Conference - Facebook
https://www.facebook.com › events › las-vegas-nevada › igns-2019-national...

https://ignsconference.com/

If they are going to have another announcement look for super26 needle set coming out party?!

the stock does look like it is under pressure. Some of that is attributed to a wide spread between the bid and the ask.And the stock has had quite a run over the last year! Churning and back filling is normal for the stock to continue a healthy rate of appreciation. Wild gyrations of some small company stock prices is symptomatic of unreal exceptions with money rushing into and out of a stock.That kind of stock movement is speculation. REPR is a small speculative stock with a good management team and a good story.

As to the Q3 earnings:
I see the company beginning to hit its stride. The company has put in place a good management team and has a diversified independence board of directors to lean on for additional guidance. The new chairman of the board, John Fletcher is highly qualified!!! See link below.

Two of the three lawsuits against the company have been settled favorably. There is no reason to believe the remaining one will have a different outcome. There will be a large reduction of legal expenses which will be more apparent in the fourth quarter.

Four months ago the FDA approved the subq formulation of Xembify. RMS is partnering with the drug maker and a few early sales might show this quarter.More sales will come in Q4 and excel through 2020.

About 6 months ago the FDA approved the super26 needle set. I expect a marketing launch of this needle set to be happening momentarily. (With a white paper??) Lets see what is said at CC.

The resent uplisting with the rebranding is the next chapter in what has been a successful story over the last year or so. As a NADAQ listed stock more and bigger investors can invest in the stock. More analyst will begin to follow the stock

So as to the Q3 earnings, I see a company executing. It does what it says it will do so I am comfortable holding the stock at this price.


https://www.marketwatch.com/press-release/rms-medical-products-names-r-john-fletcher-chairman-of-the-board-2019-09-30?mod=mw_quote_news

I have also seen positive news released just before earnings used to soften a disappointing earnings report. They could have released this info in conjunction with earnings, or after earnings to keep momentum rolling if earnings were good.

So a coin toss, imo.

I'll speculate because I am a speculator.

The timing of this announcement, before the release of earnings, would lead me to believe the earnings should be very good. There may also be some other positive headline, as you alluded to - new product etc.

Why announce the new name prior to earnings if they are going to disappoint? I am sure they want the new name associated with positive developments.

With that said the seller is back and stock under pressure again.

The Company announced the rebranding on the eve of this year’s Immunoglobulin National Society Conference (IgNS 2019) Both the management team and BOD are attending. Lots of networking.

I would not be surprised if additional announcements were made by the company. RMS has increased their R&D budget substantially and maybe there are new products to talk about??I would be interested to hear news on the super26 needle set.

Rebranding ??? I guess they've been busy with more than the uplist.

New Ticker Symbol “KRMD”
CHESTER, N.Y.--(BUSINESS WIRE)-- Repro Med Systems, Inc. (NASDAQ: REPR) (“the Company”) today announced a new dba name, KORU Medical Systems, which the Company will begin using in place of RMS Medical Products on October 24, 2019. Reflecting this change, the Company’s common stock will commence trading under the new ticker symbol “KRMD” on the NASDAQ effective October 24, 2019.

do not believe everything you read. In the past RMS has announced earnings about three weeks after the end of the quarter. This year, because of the uplisting, the earnings date with probably happen in the first week in November??

Earnings Announcement
According to CNBC website earnings are due to be reported today after market close.
I am not sure that’s accurate but it is on CNBC website.

@commando Its encouraging to see new posters and renewed interest in the company. Its a sweet match between the company products and demographic and cost driven market trends. The premium on the company's buyout price will grow as the company executes growth plan.

To be an attractive buyout prospective, RMS needs revenues sufficiently large to make an impact on the buyer.

Been an investor since 2014. @ .34. I think company will be bought out within the next 18 months. With an aging population, their products are ideal for managing care for the elderly.

One of the advantages of Sub Q infusions over IV infusions is convenience.
Let's unwrap what convenience really means. Sub q at home permits a patient or primary care provider to administer infusions at home at a time that fits their schedule. Lost work time is not just for the patient. Lost work time includes primary care givers leaving work so the patient, be it a husband, mother or child can be taken to a doctors office.

Subq administered drugs can be administered more quickly then IV infusions.
The shorter administration time of subq is also a consideration of pharma in drug development. The link below talks to these points,
https://www.cancernetwork.com/asco-multiple-myeloma/subcutaneous-vs-intravenous-daratumumab-which-better-rr-myeloma

REPR moved to the Nasdaq from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions

@blue skies
Chris on the yahoo board is me - hahaha
agree that it is worth listening to opinions that may differ.

I am still holding my full position. I would like to lighten on any jump to new highs. That's just because I am overweight REPR right now.

I was hoping the uplisting would bring a bigger rally into new highs. Perhaps that will come rest of week. Otherwise all eyes on next earnings report and I'd expect Craig Hallum analyst to check in again post entry to Nasdaq.

@Jlivermore - I also have reservations about using a single measurement, such as share price/revenues, as the sole determinate of a relative stock value. For me assessing a stock value is much more nuanced and takes into account intangibles such management and board strength.

Enjoy the ride

@Jlivermore - I went to the yahoo board and read the posts. It encouraging to see people talking about the stock. Different opinions, cross currents are a healthy part of investment. It is easy to get distracted by the noise. Negatives post propagate fear.

Different people have different matrix to evaluation a fair stock price. "Stock" on the yahoo board uses stock price/earnings and comes to the conclusion the price is too high. I am more concerned that the stock price has dramatically appreciated since(because of?) the Craig Hallum buy recommendation. And there is space underneath.

On the yahoo board, I find Chris's reply to Stock's post more inline with my assessment of RMS, "While they may not have introduced relevant "new" products the pharmaceutical industry is moving towards RMS Medical's products on multiple fronts. Big pharma wants subq products to elongate patent production. Patients want sub-q for ease of use and convenience Payers like sub-q as it cuts costs. Growing at 20% with eye on 70% margins. Room in my portfolio for REPR. A lot of room."

I would add that there is nothing sexy about the Freedom pump. It is dependable, easy to use and cost effective. I would choose those attributes in a medical device over sexy any day.

Tuesday end of the day trading looked spasmatic. I attribute that to the wide bid/ask gap and market makers prior to uplisting.

It looked like a seller(s) came in with about 20,000 shares to go. buyers marked the closing up. I'd much prefer some tighter action.

Do you have any concerns on valuation? Trading >7X trailing 12 month revenues? This point was brought up on Yahoo board and worth considering. The Craig Hallum $5.50 price target is at 8X his 2020 revenue est. of $2.4 million.

Weird price action at the end of the day. Drops to $3.62 at 3:49 before jumping to $3.90 at 4:00.

@ Jlivermore. I totally agree that the RMS management does a great job of realistically managing investor exceptions. For me this provides comfort.


The scheduled Q3 earnings release date has not been announced. The company PR department is working overtime with the uplisting. Many new eyes starting to look at the stock.

Uplisting to NASDAQ is a game changer. RMS is in the big boy sandbox playing with the big boys.

Company set the proper expectation, per upliast, and delivered again pretty much on schedule-a strong suit of the company that you pointed out. Hopefully we can get some upside pressure and test/make new highs this week.

Do we know the earnings release date? I see we released third quarter earnings 10/23 last year.

This is obviously a huge event for the company. The company has a great story! Uplisting allows investment funds that could not buy OTC stocks to trade the stock. It will be interesting to see what investment companies attend the 3Q conference call.

congrats to REPR:for going to the Naz.

thanks for both of you posting lol.

disclosure:first bot in at .46

best to all

I hope that there are more then us two reading and writing on this board

Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (“RMS Medical” or “the Company”) today announced that its common stock has been approved for listing and is expected to begin trading on the NASDAQ Capital Market on October 17, 2019 under the current symbol “REPR”. The Company’s common stock will continue to trade on the OTCQX until market close on October 16, 2019.



https://ir.rmsmedicalproducts.com/press-releases/detail/45/rms-medical-products-to-commence-trading-on-nasdaq

Uplisting

From the September 9th Craig-Hallum report "Management reiterated it has filed all necessary paperwork and should hear back from Nasdaq in the coming weeks."

We could use a good catalyst for a price jump.

@Jkivermore - I noticed a big buyer coming in.

I am hoping to hear news of an uplisting before the end of the month.

we'll see. definitely under pressure and not unusual given the large run up. Never know when the seller will be cleaned up. Large buyer stepped in today and was able to buy 40,000 shares or so on the bid at 3.40.

Let's see if we get another large buyer tomorrow at higher prices.

For the better part of my trading life I was a day trader, in fact, I was a day trader before that term even existed. The real money is made investing yet I still have to fight the old mentality of a day trader.

Still think the weekly moving avg is a key. If we can close $3.55 plus tomorrow and stabilize from there I'd be happy.

The Wednesday intra-day low was $3.20. Today's intr-day low was $3.30. The failure of the stock price to rebound, given an up market today, is problematic and does not bode well short term.

Putting on rose colored glasses, I see that a healthy retrace has occurred.
And there is comfort in the fundamentals of the company, which Craig-Hallum highlighted remain in place. The RMS story is good, the balance sheet is clean. I have faith in the RMS management team to execute the growth plan laid out. The biggest obstacle the company might face is the lack of capacity to meet future demand? This is not a terrible problem to have.

@Jlivermore - The RMS stock, has gone from $1.55 in May to a high of over $4.00 in early September. A very substantial run up. The increase in share price correlates with coverage being initiated by Craig-Hallum in the middle of June. Coincidence? I do not think so. (Craig-Hallum reiterated a buy rating with $5.50 price target after meeting with the management in September!)

Today's price action, which surprised me, dropped the price to an intraday low of $3.25.I see this as shaking out the weak hands and healthy for continued long term stock price appreciation.

The RMS strategy of developing partnerships with big pharma is starting to bare fruit. The sales of Grifols/Xemblify's subQ formulation commences in Q4. Approval outside of the U.S should follow. This revenue stream will ramp up beginning 2020.

The migration to home infusion for cost and convenience reasons will encourage drug makers to reconfigure drug formulation so they can be administered at home via SubQ.

RMS received another favorable ruling against EDEM in NY.(This is the second favorable ruling. The first was in TX.) The NY suit was the most expensive of the suits and this will save a lot of legal expenses. With two strikes against EDEM the incentive for settlement grows.

The RMS story remains largely untold. Uplisting to a major exchange expected and will bring additional buyers and coverage. Possibly becoming part of a Russell indexed fund down the line.

Breaking the 10 week moving average (3.63) is concerning to me. Hopefully we can get a rally by end of week and close above that level.
No buyers and no bounce for a couple weeks now. Color me concerned.

broke 3.40 - what do your charts tell you now?

Was hoping for new highs this week. Slightly disappointed. I am watching and hoping that the 10 week moving average holds.

8K John Fletcher replaces Dan Goldberger as Board Chairman

On September 30, 2019, Repro Med Systems, Inc. (“RMS Medical”) announced the resignation of Daniel S. Goldberger as the Company’s Executive Chairman. Mr. Goldberger will remain as a non-executive member of the RMS Medical Board of Directors

the Board of Directors of RMS Medical named R. John Fletcher, a current RMS Medical director, as Chairman.

https://ir.rmsmedicalproducts.com/sec-filings-email/content/0001161697-19-000402/form_8-k.htm

Company Presentation

REPR will be presenting at the Micro Cap Club Leadership Summit on Friday. Not sure if it’s morning or
Afternoon session


https://microcapclub.com/summit/

What I see is weakness and wide spread between the bid and the ask resulting in jerky trading. I have been putting in buy orders in between 3.65 and 3.75.

Technically Speaking

The recent low volume pull back may have concluded yesterday with a test of the 10 week moving average ($3.51) and 1 day reversal to close on 10 day MA ($4). This is the exact type of action we want to see when the stock nears the 10 week MA. Large buyer(s) stepped up.

I expect new highs in the next week or two.

@Budge - What you say for HALO increasing REPR's TAM is true for all pharma reformulating existing drugs for SubQ. The cost advantages and conveniences of home, self administered SubQ infusions is creating a paradigm shift in drug administration. REPR is well positioned to ride this wave!!

every time HALO gets an approval REPR's TAM goes up.

@ budge The company is gaining visibility as the investment community understands the story with all its nuances. The stock is tracking solidly over $3 and the uplisting expected soon. A clean balance sheet with with the current cash flow sufficient to fund operations, including and expanding R&D.

Currently there is only Craig-Hallum following the stock. Expect others to follow triggering more visibility and buying.

Everyone should do their own DD.

sounds like the wave of the future. in home med is so much cheaper that in a med facility. I think the market is enormous

@Budge - The migration to and formulation of the drugs for the SubQ market is in its early stages. The proving of a an acceptable safety profile is more a confirmation of what seems obvious. Other studies have shown that the administering of drugs via SubQ results in a more even drug level within the patients. Less spikes and valleys and hopefully less negative side effects.

budge - thanks - Sounds like a win for SubQ. Faster, cheaper and more convenient for the patients. Whats not to like?

some favorable news about new tech in medication.

Halozyme Therapeutics (NASDAQ:HALO)
Intraday Stock Chart
Today : Friday 13 September 2019

SAN DIEGO, Sept. 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its primary endpoint. The FeDeriCa study investigated a fixed-dose combination of pertuzumab (Perjeta®) and trastuzumab (Herceptin®) for subcutaneous administration using Halozyme's ENHANZE® drug delivery technology in combination with intravenous chemotherapy. The study results demonstrated non-inferior levels of Perjeta® in the blood (pharmacokinetics) compared to standard intravenous (IV) infusion of Perjeta® plus Herceptin® and chemotherapy in patients with HER2-positive early breast cancer.
"The results of the phase III FeDeriCa study represent an important development for our ENHANZE® drug delivery technology," said Dr. Helen Torley, President and CEO. "This is the first study to combine two therapeutic antibodies as a single fixed-dose subcutaneous formulation utilizing our ENHANZE® technology, thereby providing patients with HER2-positive breast cancer the possibility of a faster treatment option."
Subcutaneous administration of the fixed-dose combination of Perjeta® and Herceptin® is approximately 8 minutes for the initial loading dose and approximately 5 minutes for each subsequent maintenance dose. Intravenous administration is approximately 150 minutes for the loading dose of Perjeta® and Herceptin® using standard IV formulations and between 60-150 minutes for subsequent maintenance infusions for the combination.
The study also demonstrated that the safety profile of the fixed dose subcutaneous combination of Perjeta® and Herceptin® was consistent with the safety profile of Perjeta® and Herceptin® administered intravenously.
Full data from the FeDeriCa study will be submitted for presentation at an upcoming medical meeting and to health authorities worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).1 2
About ENHANZE® Technology
Halozyme's proprietary ENHANZE® drug-delivery technology is based on its patented recombinant human hyaluronidase enzyme (rHuPH20). rHuPH20 has been shown to remove traditional limitations on the volume of biologics that can be delivered subcutaneously (just under the skin). By using rHuPH20, some biologics and compounds that are administered intravenously may instead be delivered subcutaneously. ENHANZE® may also benefit subcutaneous biologics by reducing the need for multiple injections. This delivery has been shown in studies to reduce health care practitioner time required for administration and shorten time for drug administration.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug pegvorhyaluronidase alfa (PEGPH20), applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for the treatment of several cancers and has the potential to be used in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx for its ENHANZE® drug delivery technology. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

comparing treatment costs. Home administered self treatment such as SubQ is cheaper still. The monetary incentive to control and reduce costs benefits RMS. The tail wind is stronger then the conservative narrative story that the management is putting out. Its a question of execution. I believe that the current management team can and will do it very well.

https://www.unitedhealthgroup.com/newsroom/posts/2019-07-22-high-cost-emergency-department-visits.html#

A general FYI - the term activist investor sometimes carries with it negative connotations. Activist investors can bring to a company resources in terms of expertise and connections that are extremely valuable. I see Horton is a long term investor which assisted the company's transitions to the quality professionally run company it is today. In doing so all stockholders benefited. I see Horton sticking with the stock at this level. I suspect if the stock goes to the $6 or $8 level then there might be a review and reassessment?

As far as R&D and patent expenses, in the past, under Andy Sealfon, this was an underfunded area. RMS has brought in people such as Dr. Brian Schiller, and John Toomey to create market oriented new products. It takes time for a seed that is planted to grow. R&D will be instrumental in cementing any future government partnerships